CD38 and Miyoshi myopathy: Depending on previous therapies, performance status and comorbidities, patients with relapsed/refractory MM may benefit from pomalidomide-dexamethasone given alone or in combination with anti-CD38 antibodies (i.e., daratumumab (the APOLLO trial) [62] or isatuximab [the ICARIA-MM trial] [63], elotuzumab (the ELOQUENT-3 trial) [64], proteasome inhibitors (i.e., bortezomib [the OPTIMISMM trial] [65], carfilzomib [66] and ixazomib [67]) along with cytotoxic agents (e.g., cyclophosphamide [68]).